Insulet Corp. faces a securities class action alleging it concealed defective manufacturing controls at its Acton, Massachusetts facility. Shares fell roughly $24 across two Medical Device Corrections affecting millions of Omnipod devices. The lead plaintiff deadline is Aug. 31, 2026.
Shares of Insulet Corp. fell roughly $24 across two corrective disclosures as investors pursue a securities class action over alleged manufacturing defects at its Acton, Massachusetts facility.
"Individual officers who sign SEC certifications bear personal responsibility for the accuracy of corporate disclosures," Joseph E. Levi, founding partner at Levi & Korsinsky, said. "When executives make specific safety claims while selling millions in stock, investors deserve to know whether those claims were supported by the facts known internally."
The lawsuit, filed on behalf of purchasers of Insulet (NASDAQ: PODD) securities between Feb. 21, 2025 and May 26, 2026, alleges the company made materially false statements about its manufacturing controls and the safety of its Omnipod insulin delivery systems. The complaint names Insulet and six current and former executives, including CEO Ashley McEvoy, former CEO James Hollingshead, CFO Flavia Pease, former CFO Ana Chadwick, Chief Medical Officer Trang Ly, and former EVP and COO Eric Benjamin.
The stock declined $16.23 per share (6.88 percent) on March 13, 2026, following the first Medical Device Correction, and an additional $7.79 per share (5.07 percent) on May 27, 2026, after the second. The May correction affected approximately 7 million Pods across Omnipod 5, Omnipod Dash, and Omnipod Eros, all traced to cannula handling at the Acton facility. Shares closed at $146.01 after the second disclosure, down from roughly $236 at the start of the class period.
The complaint alleges Benjamin sold 12,594 shares for approximately $3.7 million during the class period, the largest insider disposition among individual defendants. Former CEO Hollingshead sold 6,821 shares for about $1.8 million, and former CFO Chadwick sold 1,765 shares for approximately $441,691. Total insider proceeds exceeded $5.9 million, with Benjamin's sales accounting for more than 62 percent of the total.
Benjamin, who served as Chief Product and Customer Experience Officer before his promotion to EVP and COO in August 2025, told investors on the Q2 2025 earnings call that "Omnipod 5 is safe, effective, understood to be really easy to use." The complaint contends this statement was misleading because manufacturing controls at the Acton facility were already defective.
Insulet invested over $1 billion in manufacturing capabilities over the prior decade and targeted 70 percent gross profit margins at scale, according to the complaint. The March and May 2026 Medical Device Corrections involved the same cannula-related defect, suggesting initial corrective actions failed to address broader quality-control issues.
Investors seeking to serve as lead plaintiff must file papers by Aug. 31, 2026. The deadline applies only to investors seeking lead plaintiff status; class members who do not apply may still participate in any recovery.
The lawsuit tests whether Insulet's quality-control disclosures kept pace with its manufacturing expansion. The next milestone is the lead plaintiff deadline on Aug. 31, after which the court will appoint a representative to direct the litigation.
This article is for informational purposes only and does not constitute investment advice.
